The Valley of Death Is Not a Science Problem. It’s a Capital Allocation Problem.

In February 2026, InnoDexis tracked 222 innovations across 9 TRL levels in 17 countries.

What we found should concern every serious investor and R&D leader.

81 innovations sit at TRL 3–4 — lab validated, concept proven, technically sound.

Only 23 reached TRL 5–6.

That’s a 72% attrition rate between proof and pilot.

This isn’t about weak science. It’s about weak bridges.

Bridge capital doesn’t follow validation. It follows visibility.

And most TRL 3–4 breakthroughs are invisible - until they’re acquired cheaply… or quietly die.

Here’s what makes this urgent:

Of the 23 that crossed into TRL 5–6, 7 already carry High Disruption signals.

Meaning the next category leaders are not at TRL 9. They’re stranded at TRL 4–5.

So the real strategic question is:

Are you allocating deliberately into the Valley of Death - or only discovering winners after someone else funded the crossing?

The firms that build signal detection at TRL 4–6 won’t compete on valuation later. They’ll set it.